Physicians' Academy for Cardiovascular Education

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark

Can sex-specific thresholds for hs-troponin improve diagnosis of myocardial infarction?

3' education - Aug. 28, 2018 - Prof. Nicholas Mills, Edinburgh, UK

Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe

3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada

Direct Factor Xa inhibitor does not mitigate worsening of heart failure in HFrEF patients

3' education - Aug. 27, 2018 - Prof. Faiez Zannad, Vandoeuvre Les Nancy, France

In a primary prevention setting of diabetes patients, aspirin did not give overall benefit

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT

3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands

Weight loss agent showed CV safety in high-risk patients with overweight or obesity

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No CV benefit with omega-3 fatty acid supplements

3' education - Aug. 26, 2018

PCSK9 as target for treatment: The genetic validation

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK
Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

Prof. Ference shows that PCSK9 inhibition has biologically and therapeutically equivalent effects on the risk of CVD as observed with statins.

ESC debate | First-line therapies in HFrEF - ACE inhibitors or sacubitril/valsartan?

ESC 2018 - debates

ESC 2018 The benefit of sacubitril/valsartan in HFrEF is not subject to debate, but opinions do vary on when to use it. An impression of the arguments on whether or not it should be the starting treatment.

Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy

3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy
In a randomized trial treatment with tafamidis resulted in impressive, significantly reduced mortality and hospitalization due to CV events in patients with ATTR-CM and HF.

ESC 2018 In a randomized trial treatment with tafamidis resulted in impressive, significant reduced mortality and hospitality due to CV events in patients with ATTR-CM and HF.

Surprising result: Association very high levels of HDL-c and increased risk of CV events

3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS
Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.

ESC 2018 Dr Allard-Ratick shares the surprising result that HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI in adults with CV disease.

THE GREAT DEBATE: Thrombocardiology post-COMPASS

ESC 2018 - Debates
ESC 2018 - Debates

ESC 2018 In one of this year’s organized debates, it was discussed how the COMPASS trial results should or should not change clinical practice; an impression of the arguments of both sides.

ARNI can be initiated early and safely in hospitalized patients after acute HF episode

News - Sep. 3, 2018

ESC 2018 The TRANSITION study results show that sacubitril/valsartan was safe and well-tolerated in a wide range of HFrEF patients who have been stabilized after an acute HF episode , showing CV safety.

Low-carbohydrate diets: increased risk of mortality in adults

ESC 2018 - Munich

News - Aug. 30, 2018

ESC 2018 The NHANES cohort study showed that low-carbohydrate diets increase the risk of mortality in adults, a finding that was validated by a meta-analysis of pooled prospective cohort studies.

Very high levels of HDL-c are associated with increased risk of CV events

ESC 2018 - Munich

News - Aug. 29, 2018

ESC 2018 In adults with CV disease, HDL-C levels >60 mg/dl (1.5 mmol/L) were associated with a nearly two-fold increase in the risk of CV death or MI.

Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients

3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark
Results of the VERDICT trial were neutral for an early intervention strategy compared to standard management in NSTEMI patients. However, a beneficial effect of early intervention was observed in those with a GRACE score >140.

ESC 2018 Results of the VERDICT trial were neutral for an early intervention strategy compared to standard management in NSTEMI patients. However, a beneficial effect of early intervention was observed in those with a GRACE score >140.

Can sex-specific thresholds for hs-troponin improve diagnosis of myocardial infarction?

3' education - Aug. 28, 2018 - Prof. Nicholas Mills, Edinburgh, UK
Prof Mills discusses the results of a high-sensitivity troponin test for the diagnosis of MI on outcomes in the High-STEACS trial and gives explanations for the unexpected results.

ESC 2018 Prof Mills discusses the results of a high-sensitivity troponin test for the diagnosis of MI on outcomes in the High-STEACS trial and gives explanations for the unexpected results.

Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe

3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada
In an analysis of four large global studies, higher healthy diet score was related to a lower risk of mortality, MI and stroke. Dr. Mente discusses how the healthy diet score is calculated and talks about the results of these four studies.

ESC 2018 In an analysis of four large global studies, higher healthy diet score was related to a lower risk of mortality, MI and stroke. Dr. Mente discusses how the healthy diet score is calculated and talks about the results of these four studies.

Reduced CV disease and mortality with higher healthy diet score worldwide

ESC 2018 - Munich

News - Aug. 28, 2018

ESC 2018 The PURE cohort study and three other studies showed reduced risk of CV disease and mortality with higher healthy diet score in general populations worldwide.

ESC 2018
ESC 2018